ストックスクリーナーアプリを入手
0.00
100.00%
-9.71
前日終値:
$9.71
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$39.28M
収益：
$147.75M
当期純損益:
$-284.23M
株価収益率:
0.00
EPS:
-2.93
ネットキャッシュフロー:
$-317.54M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$12.60
Fibrogen Inc Stock (FGEN) Company Profile
Compare FGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.00 | 39.28M | 147.75M | -284.23M | -317.54M | -2.93 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 113.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.87 | 64.45B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.83 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.91 | 40.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
163.07 | 33.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-26 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2023-06-26 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | アップグレード | Stifel | Hold → Buy |
| 2023-01-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-09-22 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-07-16 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-03-31 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-03-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-26 | 開始されました | Raymond James | Underperform |
| 2020-07-10 | 再開されました | Stifel | Buy |
| 2020-05-01 | 開始されました | Cowen | Market Perform |
| 2020-04-27 | 開始されました | BofA/Merrill | Neutral |
| 2019-05-29 | 再開されました | Goldman | Neutral |
| 2019-05-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | 開始されました | Piper Jaffray | Neutral |
| 2019-02-11 | 再開されました | Stifel | Buy |
| 2018-12-19 | アップグレード | Citigroup | Neutral → Buy |
| 2017-08-08 | 繰り返されました | Leerink Partners | Outperform |
| 2017-08-08 | 繰り返されました | Stifel | Buy |
| 2017-07-21 | ダウングレード | Goldman | Buy → Neutral |
| 2017-07-11 | 開始されました | Jefferies | Buy |
| 2016-02-11 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
| 2015-12-04 | 開始されました | Citigroup | Buy |
| 2015-09-23 | 開始されました | Lake Street | Hold |
| 2015-07-29 | 開始されました | Citigroup | Buy |
| 2015-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2014-12-09 | 開始されました | Stifel | Buy |
すべてを表示
Fibrogen Inc (FGEN) 最新ニュース
FibroGen Inc stock (US3156631046): volatility after Nasdaq delisting and Kynbio merger plans - AD HOC NEWS
KYNTRA BIO (KYNB) CEO Thane Wettig purchases 2,800 shares at $7.09 - Stock Titan
Armistice Capital (FGEN) reports 400,000-share, 9.88% position (May 2026) - Stock Titan
Health News Roundup: FibroGen's neuromuscular disorder therapy fails late-stage study; Merck sues US government to halt Medicare drug price negotiation and more - Devdiscourse
FibroGen, Inc. (FGEN) - Minichart
Kyntra Bio (Nasdaq: KYNB) Q1 2026 results show higher revenue, ongoing R&D spend - Stock Titan
Kyntra Bio stock (US3156631046): Q1 2026 revenue rises to $3.7M amid pipeline advances - AD HOC NEWS
Kyntra Bio (NASDAQ: FGEN) Q1 2026 results, oncology pipeline and cash runway - Stock Titan
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against FibroGen, Inc.FGEN - TMX Newsfile
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against FibroGen, Inc.FGEN - TMX Newsfile
Kyntra Bio (NASDAQ: FGEN) details 2026 virtual meeting and pay vote - Stock Titan
FibroGen Shareholder Alert - TMX Newsfile
FibroGen Inc stock (US3156631046): Is its hypoxia-inducible factor focus still the real test for bio - AD HOC NEWS
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
Nasdaq Moves: Can FibroGen Inc sustain its profitability2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Retail Trends: What is the target price for FibroGen Inc stock2026 Summary & Verified Short-Term Plans - baoquankhu1.vn
Sentiment Review: Will FibroGen Inc benefit from government policy2026 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
FibroGen Inc stock: What investors need to know now - AD HOC NEWS
Kyntra Bio CEO to webcast April 13 presentation at Needham event - Stock Titan
Aug Sentiment: Is FibroGen Inc stock a value trap2026 Momentum Check & Reliable Momentum Entry Alerts - baoquankhu1.vn
FibroGen Inc Stock: Biotech Innovator Focused on Hypoxia Pathways and Oncology for Long-Term Investo - AD HOC NEWS
FGEN SEC FilingsFibrogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Setups: What is the long term forecast for FibroGen Inc stock2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Kyntra Bio (MEX:KYNB) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
Aug Macro: Can FibroGen Inc sustain its profitability2026 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
Rate Cut: What is the long term forecast for FibroGen Inc stock2026 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
FibroGen Inc stock leads biotech gains on China asset sale and FDA update amid Q4 earnings scrutiny - AD HOC NEWS
FibroGen Inc stock faces renewed scrutiny amid expanding interstitial lung disease pipeline competit - AD HOC NEWS
If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
FibroGen Inc stock faces scrutiny ahead of delayed Q4 earnings release amid pipeline pressures - AD HOC NEWS
Revenue of Fibrogen from 2020 to 2024 - Statista
Breakout Watch: Is FibroGen Inc stock a value trapPortfolio Update Report & Smart Investment Allocation Insights - baoquankhu1.vn
KYNB: Cash runway extended to 2028 as FG-3246 and roxadustat advance in key late-stage trials - TradingView
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kyntra Bio: Q4 Earnings Snapshot - marketscreener.com
Kyntra Bio (NASDAQ: KYNB) pivots to oncology and advances FG-3246, roxadustat - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
New prostate cancer drug trial advances as Kyntra Bio cuts 2025 loss - Stock Titan
FibroGen Q4 2025 earnings preview - MSN
FibroGen (KYNB) Set to Announce Q4 Earnings with Significant Dec - gurufocus.com
Bull Run: What is the long term forecast for FibroGen Inc stock2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Kyntra Bio (KYNB) CEO reports 277-share tax withholding event - Stock Titan
Tax withholding slightly trims Kyntra Bio (KYNB) CFO share holdings - Stock Titan
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Gains Report: Is FibroGen Inc stock a value trap2025 Market WrapUp & Long Hold Capital Preservation Plans - baoquankhu1.vn
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca - MSN
Quarterly Earnings: What is the target price for FibroGen Inc stockJobs Report & Safe Capital Investment Plans - baoquankhu1.vn
FGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fibrogen Inc (FGEN) 財務データ
収益
当期純利益
現金流量
EPS
Fibrogen Inc (FGEN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
1.27%
0.82%
大文字化:
|
ボリューム (24 時間):